Lori A. Birder

Featured in: Favicon

Articles

Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma

Mar 26, 2024 | europeanurology.com | Marcus J. Drake |Lori A. Birder

Rosenberg JE, Powles T, Sonpavde GP, et al. To read this article in full you will need to make a paymentSubscribe to European UrologyReferencesEV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol. 34: 1047-1054Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med.
Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma

Mar 26, 2024 | europeanurology.com | Marcus J. Drake |Lori A. Birder

Rosenberg JE, Powles T, Sonpavde GP, et al. To read this article in full you will need to make a paymentSubscribe to European UrologyReferencesEV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol. 34: 1047-1054Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.